Bios Capital Management

$34M 13F equity value
6 Holdings
Quarter ended September 30, 2026

The latest 13F on file for Bios Capital Management covers the quarter ended September 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.

Top Holdings

TickerCompanySharesValueWeight
IRDOPUS GENETICS INC3,683,429$18M52.2%
ACTUACTUATE THERAPEUTICS INC10,049,996$8M22.9%
CGTXCOGNITION THERAPEUTICS INC6,000,000$6M16.9%
RNTXREIN THERAPEUTICS INC2,982,375$2M7.0%
LTRNLANTERN PHARMA INC235,895$238,2540.7%
INABIN8BIO INC80,957$107,6730.3%

Track Bios Capital Management's 13F portfolio: $34M in reported holdings, 6 positions. Top holdings and quarterly changes on SentiSense.

This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}